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Erratum 
Please be advised that there is an error in Table I of 
“The  Role  of  HER2-targeted  Therapies  in  Women 
with HER2-Overexpressing Metastatic Breast Cancer” 
by Dent et al. which appeared in Current Oncology 
  Volume 16, Number 4  on page 236 in print, and page 
table i   Efficacy results from pivotal first-line metastatic breast cancer trials
Clinical 
endpoint
Trial arms 
Slamon et al., 2001 18
(n=469)
Trial arms 
Marty et al., 2005 and 2006 19,20
(n=186)
Trastuzumab AND 
[paclitaxel OR 
(anthracycline AND 
cyclophosphamide)]
Paclitaxel OR 
(anthracycline AND 
cyclophosphamide)
Trastuzumab AND 
docetaxel
Docetaxel 
alone
Median orr (%) 50 32 61 34
p<0.001 p=0.0002
Median dr (months) 9.1 6.1 11.7 5.7
p<0.001 p=0.009
Median ttp (months) 7.4 4.6 11.7 6.1
p<0.001 p=0.0001
Median os (months) 25.1 20.3 31.2 22.7
p=0.046 p=0.0325a
a     Trial survival results were updated at the 2006 San Antonio Breast Cancer Symposium. The superior survival benefit for trastuzumab plus 
docetaxel over docetaxel alone was maintained (31.2 months vs. 22.7 months); however, the survival difference was no longer significant 
(p = 0.0876), perhaps because most of the patients randomized to docetaxel alone (57%) subsequently crossed over to receive trastuzumab.
orr = objective response rate; dr = duration of response; ttp = time to progression; os = overall survival.
26 online. The median ttp in the Slamon et al. trial in 
the column labeled “Trastuzumab AND [paclitaxel OR 
(anthracycline AND cyclophosphamide)]” should read 7.4 
not 4.7 as originally printed.  The corrected version of 
the table can be found below.